Bharat Parenterals Ltd (541096)
Investor Presentation for the Quarter ended on June 30, 2026
AI summary
- Consolidated Q1 FY27 revenue ₹93.7 Cr (-19.2% YoY), EBITDA ₹8.5 Cr (9.1% margin), PAT loss ₹3.6 Cr
- Standalone revenue down 41.2% YoY to ₹55.5 Cr; EBITDA margin 12.3%, PAT ₹3.7 Cr
- Innoxel revenue +165% YoY to ₹21.4 Cr; EBITDA loss narrowed to ₹1.8 Cr; commercial CMO supply starts Q2 FY27
- Varenyam Healthcare revenue +52.2% YoY to ₹25.1 Cr; EBITDA margin 12.4%; expanding field force and new brands
- FY27 guidance: Standalone growth 10-15%, EBITDA margin 10-15%; Innoxel growth 35-45%, EBITDA margin 20-25%; Varenyam growth 20-25%, EBITDA margin 8-13%
- Varenyam Bio pre-revenue; commissioning targeted Sep 2027, first EU-GMP filing Q1 FY29
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 541096 — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add 541096 to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Bharat Parenterals Ltd
Important.
The summary above is generated automatically from Bharat Parenterals Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.